[Good news about pulmonary hypertension].
Barberà
J
J
Servei de Pneumologia i Allèrgia Respiratòria. Hospital Clínic. Universitat de Barcelona, Spain. jbarbera@clinic.ub.es
D000925:Anticoagulants / Q000627:therapeutic use; D052006:Bone Morphogenetic Protein Receptors, Type II; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D004730:Endothelium, Vascular / Q000473:pathology; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000473:pathology; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D009154:Mutation; D015995:Prevalence; D017346:Protein Serine-Threonine Kinases / Q000172:deficiency / Q000235:genetics*; D016019:Survival Analysis; D014944:World Health Organization
D000925:Anticoagulants; D002121:Calcium Channel Blockers; D011464:Epoprostenol; D017346:Protein Serine-Threonine Kinases; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II